Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology

Journal of Molecular Diagnostics

Volumn 15, Issue 6, 2013, Pages 819-826

  Zhang, Hui ^a   Liu, Deruo ^b   Li, Shanqing ^c   Zheng, Yongqing ^d   Yang, Xinjie ^a   Li, Xi ^a   Zhang, Quan ^a   Qin, Na ^a   Lu, Jialin ^a   Ren Heidenreich, Lifen ^d   Yang, Huiyi ^d   Wu, Yuhua ^a   Zhang, Xinyong ^a   Nong, Jingying ^a   Sun, Yifen ^a   Zhang, Shucai ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b Chinese Japanese Friendship Hospital   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d Guangzhou Technology Innovation Base   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; ARTICLE; BLOOD; EXON; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIQUIDCHIP TECHNOLOGY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SEX DIFFERENCE; SMOKING; SOMATIC MUTATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM STAGING; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84885980911     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2013.06.006     Document Type: Article

References (48)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. R. Govindan, N. Page, D. Morgensztern, W. Read, R. Tierney, A. Vlahiotis, E.L. Spitznagel, and J. Piccirillo Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 2006 4539 4544
3. S. Oizumi, K. Kobayashi, A. Inoue, M. Maemondo, S. Sugawara, H. Yoshizawa, H. Isobe, M. Harada, I. Kinoshita, S. Okinaga, T. Kato, T. Harada, A. Gemma, Y. Saijo, Y. Yokomizo, S. Morita, K. Hagiwara, and T. Nukiwa Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial Oncologist 17 2012 863 870
4. P.A. Bunn Jr., and R.C. Doebele Genetic testing for lung cancer: reflex versus clinical selection J Clin Oncol 29 2011 1943 1945
5. H. Shigematsu, and A.F. Gazdar Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers Int J Cancer 118 2006 257 262
6. M.S. Tsao, A. Sakurada, J.C. Cutz, C.Q. Zhu, S. Kamel-Reid, J. Squire, I. Lorimer, T. Zhang, N. Liu, M. Daneshmand, P. Marrano, G. da Cunha Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater, and F.A. Shepherd Erlotinib in lung cancer-molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
7. S.V. Sharma, D.W. Bell, J. Settleman, and D.A. Haber Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
8. T. Mitsudomi, and Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 2007 1817 1824
9. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Jr., W.A. Franklin, R. Dziadziuszko, N. Thatcher, A. Chang, P. Parikh, J.R. Pereira, T. Ciuleanu, J. von Pawel, C. Watkins, A. Flannery, G. Ellison, E. Donald, L. Knight, D. Parums, N. Botwood, and B. Holloway Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 2006 5034 5042
10. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, B.W. Brannigan, P.L. Harris, S.M. Haserlat, J.G. Supko, F.G. Haluska, D.N. Louis, D.C. Christiani, J. Settleman, and D.A. Haber Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
11. J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, and M. Meyerson EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
12. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, and H. Varmus EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311
13. J.A. Engelman, T. Mukohara, K. Zejnullahu, E. Lifshits, A.M. Borras, C.M. Gale, G.N. Naumov, B.Y. Yeap, E. Jarrell, J. Sun, S. Tracy, X. Zhao, J.V. Heymach, B.E. Johnson, L.C. Cantley, and P.A. Janne Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer J Clin Invest 116 2006 2695 2706
14. G.R. Oxnard, M.E. Arcila, C.S. Sima, G.J. Riely, J. Chmielecki, M.G. Kris, W. Pao, M. Ladanyi, and V.A. Miller Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation Clin Cancer Res 17 2011 1616 1622
15. S.W. Han, T.Y. Kim, Y.K. Jeon, P.G. Hwang, S.A. Im, K.H. Lee, J.H. Kim, D.W. Kim, D.S. Heo, N.K. Kim, D.H. Chung, and Y.J. Bang Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation Clin Cancer Res 12 2006 2538 2544
16. N. van Zandwijk, A. Mathy, L. Boerrigter, H. Ruijter, I. Tielen, D. de Jong, P. Baas, S. Burgers, and P. Nederlof EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer Ann Oncol 18 2007 99 103
17. D.A. Eberhard, B.E. Johnson, L.C. Amler, A.D. Goddard, S.L. Heldens, R.S. Herbst, W.L. Ince, P.A. Janne, T. Januario, D.H. Johnson, P. Klein, V.A. Miller, M.A. Ostland, D.A. Ramies, D. Sebisanovic, J.A. Stinson, Y.R. Zhang, S. Seshagiri, and K.J. Hillan Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
18. C. Mao, L.X. Qiu, R.Y. Liao, F.B. Du, H. Ding, W.C. Yang, J. Li, and Q. Chen KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies Lung Cancer 69 2010 272 278
19. W. Pao, T.Y. Wang, G.J. Riely, V.A. Miller, Q. Pan, M. Ladanyi, M.F. Zakowski, R.T. Heelan, M.G. Kris, and H.E. Varmus KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
20. S.A. Yousem, M. Nikiforova, and Y. Nikiforov The histopathology of BRAF-V600E-mutated lung adenocarcinoma Am J Surg Pathol 32 2008 1317 1321
21. H. Sasaki, O. Kawano, K. Endo, E. Suzuki, H. Haneda, H. Yukiue, Y. Kobayashi, M. Yano, and Y. Fujii Uncommon V599E BRAF mutations in Japanese patients with lung cancer J Surg Res 133 2006 203 206
22. B. Karakas, K.E. Bachman, and B.H. Park Mutation of the PI3KCA oncogene in human cancers Br J Cancer 94 2006 455 459
23. P.B. Gahan, and R. Swaminathan Circulating nucleic acids in plasma and serum. Recent developments Ann N Y Acad Sci 1137 2008 1 6
24. H. Kimura, K. Kasahara, M. Kawaishi, H. Kunitoh, T. Tamura, B. Holloway, and K. Nishio Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer Clin Cancer Res 12 2006 3915 3921
25. C. He, M. Liu, C. Zhou, J. Zhang, M. Ouyang, N. Zhong, and J. Xu Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer Int J Cancer 125 2009 2393 2399
26. H. Bai, L. Mao, H.S. Wang, J. Zhao, L. Yang, T.T. An, X. Wang, C.J. Duan, N.M. Wu, Z.Q. Guo, Y.X. Liu, H.N. Liu, Y.Y. Wang, and J. Wang Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer J Clin Oncol 27 2009 2653 2659
27. T.K. Yung, K.C. Chan, T.S. Mok, J. Tong, K.F. To, and Y.M. Lo Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients Clin Cancer Res 15 2009 2076 2084
28. S.G. Wu, C.H. Gow, C.J. Yu, Y.L. Chang, C.H. Yang, Y.C. Hsu, J.Y. Shih, Y.C. Lee, and P.C. Yang Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma Eur Respir J 32 2008 924 930
29. X. Zhang, Y. Zhao, M. Wang, W.S. Yap, and A.Y. Chang Detection and comparison of epidermal growth factor receptor mutations in cells and fluid of malignant pleural effusion in non-small cell lung cancer Lung Cancer 60 2008 175 182
30. H. Asano, S. Toyooka, M. Tokumo, K. Ichimura, K. Aoe, S. Ito, K. Tsukuda, M. Ouchida, M. Aoe, H. Katayama, A. Hiraki, K. Sugi, K. Kiura, H. Date, and N. Shimizu Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay Clin Cancer Res 12 2006 43 48
31. S. Wu, Z. Zhu, J. He, X. Luo, J. Xu, and L. Ren-Heidenreich A novel mutant-enriched liquidchip technology for the qualitative detection of somatic mutations in KRAS gene from both serum and tissue samples Clin Chem Lab Med 48 2010 1103 1106
32. G. Li, X. Luo, J. He, Z. Zhu, G. Yu, H. Qin, T. Zeng, Z. Liu, S. Wu, J. Xu, and L. Ren-Heidenreich A novel liquidchip platform for simultaneous detection of 70 alleles of DNA somatic mutations on EGFR, KRAS, BRAF and PI3KCA from formalin-fixed and paraffin-embedded slides containing tumor tissue Clin Chem Lab Med 49 2011 191 195
33. L.H. Sobin, M.K. Gospodarowicz, and C.Z. Wittekind International Union Against Cancer (UICC): TNM Classification of Malignant Tumours 7th Edition 2009 Oxford, Wiley-Blackwell 138 146
34. M.M. Oken, R.H. Creech, D.C. Tormey, J. Horton, T.E. Davis, E.T. McFadden, and P.P. Carbone Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 1982 649 655
35. S.F. Huang, H.P. Liu, L.H. Li, Y.C. Ku, Y.N. Fu, H.Y. Tsai, Y.T. Chen, Y.F. Lin, W.C. Chang, H.P. Kuo, Y.C. Wu, Y.R. Chen, and S.F. Tsai High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan Clin Cancer Res 10 2004 8195 8203
36. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 2004 8919 8923
37. A. Hata, N. Katakami, S. Fujita, R. Kaji, Y. Imai, Y. Takahashi, T. Nishimura, K. Tomii, and K. Ishihara Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma J Thorac Oncol 5 2010 1197 1200
38. T.W. Jang, C.H. Oak, H.K. Chang, S.J. Suo, and M.H. Jung EGFR and KRAS mutations in patients with adenocarcinoma of the lung Korean J Intern Med 24 2009 48 54
39. O. Kawano, H. Sasaki, K. Endo, E. Suzuki, H. Haneda, H. Yukiue, Y. Kobayashi, M. Yano, and Y. Fujii PI3KCA mutation status in Japanese lung cancer patients Lung Cancer 54 2006 209 215
40. H.H. Nelson, D.C. Christiani, E.J. Mark, J.K. Wiencke, J.C. Wain, and K.T. Kelsey Implications and prognostic value of K-ras mutation for early-stage lung cancer in women J Natl Cancer Inst 91 1999 2032 2038
41. J.L. Marks, M.D. McLellan, M.F. Zakowski, A.E. Lash, Y. Kasai, S. Broderick, I.S. Sarkaria, D. Pham, B. Singh, T.L. Miner, G.A. Fewell, L.L. Fulton, E.R. Mardis, R.K. Wilson, M.G. Kris, V.W. Rusch, H. Varmus, and W. Pao Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4 PLoS One 2 2007 e426
42. M. Rogosnitzky, and R. Danks Validation of blood testing for K-ras mutations in colorectal and pancreatic cancer Anticancer Res 30 2010 2943 2947
43. S. Wang, T. An, J. Wang, J. Zhao, Z. Wang, M. Zhuo, H. Bai, L. Yang, Y. Zhang, X. Wang, J. Duan, Y. Wang, Q. Guo, and M. Wu Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer Clin Cancer Res 16 2010 1324 1330
44. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, J. von Pawel, S. Thongprasert, E.H. Tan, K. Pemberton, V. Archer, and K. Carroll Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
45. R.S. Herbst, A.M. Maddox, M.L. Rothenberg, E.J. Small, E.H. Rubin, J. Baselga, F. Rojo, W.K. Hong, H. Swaisland, S.D. Averbuch, J. Ochs, and P.M. LoRusso Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial J Clin Oncol 20 2002 3815 3825
46. P.A. Janne, J.A. Engelman, and B.E. Johnson Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology J Clin Oncol 23 2005 3227 3234
47. A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore, A. Chella, P.P. Camplese, T. Iarussi, F. Mucilli, A. Mezzetti, F. Cuccurullo, R. Sacco, and F. Buttitta EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment J Clin Oncol 23 2005 857 865
48. I.Y. Tam, L.P. Chung, W.S. Suen, E. Wang, M.C. Wong, K.K. Ho, W.K. Lam, S.W. Chiu, L. Girard, J.D. Minna, A.F. Gazdar, and M.P. Wong Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features Clin Cancer Res 12 2006 1647 1653